Contract research organisation Domainex has named Hayley French as its new chief executive officer, bringing legal, scientific, and strategic expertise to the leadership role.

French joins the UK-based CRO with a background in microbiology and law, and extensive experience across the life sciences sector. She has held a range of senior positions in pharma and biotech companies, with a focus on strategic development, commercialisation, and operational leadership.

Most recently, she served as CEO of Apitope International NV prior to its acquisition by Worg Pharmaceuticals. Earlier in her career, she held legal roles at Novartis, Bird & Bird, and CAMR, and began her journey in life sciences at UCL Ventures.

“We are excited to welcome Hayley to Domainex,” said Eddy Littler, chairman of Domainex.

“Her profound understanding of the biotechnology landscape, strategic vision, and exemplary leadership skills render her the ideal individual to steer Domainex through its next stage of growth.”

Littler, who had been serving as interim CEO, returns to his role as non-executive Chairman following French’s appointment.

French said she is looking forward to working with the team to accelerate innovation and delivery:

“Domainex is renowned for its innovative approach to drug discovery and its unwavering commitment to delivering high-quality results. I am eager to build on this strong foundation.”

Her appointment is effective immediately. French will be based at Domainex’s headquarters in Cambridge, UK.